The infectious disease in vitro diagnostics market size is estimated to be USD 113,752.1 million in 2022 and is expected to witness a CAGR of 7.55% during the forecast period 2023-2033. Increasing elderly population that are more susceptible to infectious diseases, rising demand for PoC testing due to the pandemic, the improved understanding of early testing, and surge in prevalence of infectious diseases are factors contributing to the market growth. Additionally, shift from centralised laboratories to decentralised point-of-care services is expected to propel the market growth. However, is expected to hinder the growth.

Shift from centralised laboratories to decentralised point-of-care services is predicted to fuel the market growth. POC testing helps in early identification and treatment of a number of infectious disorders, including Chlamydia, gonorrhoea, and influenza, among others. POC testing in a decentralised system helps patients and doctors keep a record of infectious diseases and enhances clinical efficiency. Point-of-care (POC) testing is frequently carried out for diagnosis at or close to the location where a patient first interacts with the healthcare system. POC tests may enhance the way infectious illness patients are managed.

Increasing elderly population that are more susceptible to infectious diseases is expected to support the market growth. As ageing is the primary risk factor for the emergence of diseases including cardiovascular and neurological disorders, rising geriatric population is anticipated to have a significant impact on the market. A patient’s susceptibility to infectious diseases rises as they age as their immune system becomes weaker.

Segmentation

By Product

The market is divided into reagents, instruments, and software. In the global market, the reagents segment accounted for the largest revenue share in 2022 owing to the extensive use of chemicals during testing. The COVID-19 testing programmes, which confirm both positive and negative tests, are also increasing the number of reagents used. For instance, SRL Inc. announced the launch of a new laboratory company named “IVD and COVID-19 testing” in February 2022. This service is intended to precisely confirm negative findings. The increase in PCR instrument installation for SARS-CoV-2 tests led to a sharp increase in the instruments segment. Rapid innovation is increasingly being prioritised in efforts to gain a competitive edge. For instance, the FDA licensed the InspectIR COVID-19 Breathalyzer in April 2022 for quick testing in places like doctors’ offices and mobile testing facilities.

By Technology

The market is divided into microbiology, molecular diagnostics, immunoassay, and others. In 2022, the microbiology segment accounted for the highest revenue share due to the fact that molecular diagnostics are used for all major parasitic, bacterial, and viral diseases. These tests are more advanced and do not have the limitations of conventional testing methods, such as irregular microbe growth in manually created media, extended turnaround times, and low sensitivity. The immunoassay technology market is anticipated to grow gradually at a CAGR during the forecast period due to rise in the need for fast PoC tests, companies are concentrating on the development and commercialization of immunoassays for COVID-19 diagnosis. For instance, in October 2020 Creative Diagnostics released SARS-CoV-2 immunoassay kits for the detection of SARS-CoV-2 antigens and antibodies.

By Application

The market is segregated into VRE, MRSA, clostridium difficile, respiratory virus, HIV, CRE, hepatitis B, candida, covid-19, chlamydia, gonorrhea, streptococcus, and others. In the global market, the covid-19 segment accounted for the largest revenue share in 2022 owing to the increasing use of SARS-CoV-2 testing to prevent the infection’s transmission. Along with the introduction of novel products, government programmes to improve public testing have also been one of the key factors in the segment’s growth. Improved testing is responsible for the rapid expansion of the TB and HIV categories. The development of novel diagnostic technologies that enable for testing of SARS-CoV-2 as well as influenza with discrimination between the two conditions to speed treatment has also increased the pace of influenza testing in the respiratory virus segment.

By Test Location

The market is segmented into central laboratories, point of care, and others. In 2022, the central laboratories segment accounted for the largest revenue share owing to the fact that laboratory-based tests guarantee greater accuracy, when compared to point of care diagnostics. The availability of complex tests that cannot be performed in PoC and homecare settings is another advantage. Additionally, the availability of procedures that enable home sample collection and lab testing makes testing extremely simple for patients. For instance, LabCorp’s home collection kit that enables simultaneous testing for the flu and SARS-CoV-2 gained EUA from the FDA in October 2021. The demand for point-of-care diagnostics has increased due to the growing demand for faster response times. The COVID-19 has promoted segment growth and increased demand for these products. Products in this market segment have a competitive advantage due to their quick turnaround time and lack of complexity.

Regional Markets

In 2022, North America region accounted for the highest revenue in the infectious disease in vitro diagnostics market and is expected to maintain its dominance during the forecast period. This is attributed to the existence of a supportive and flexible regulatory framework, the presence of significant industry players, and the emphasis on enhancing disease surveillance by performing additional tests. The Asia Pacific region to exhibit the greatest CAGR due to rising incidence of infectious diseases. The region’s growth is also being supported by the expanding access to healthcare in developing countries like India. The growing geriatric population in countries including Japan is another factor driving the use of IVD tests.

Competitor Insights

Some of the key players operating in the infectious disease in vitro diagnostics market are F. Hoffmann-La Roche, Ltd., OraSure Technologies, Inc., bioMérieux SA, BD, Danaher, Quidel Corp., Hologic, Inc. (Gen-Probe), Siemens Healthineers AG, QIAGEN, Abbott, and Bio-Rad Laboratories, Inc.

To achieve a competitive edge, these businesses are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, Quest Diagnostics and Memorial Hermann Health System collaborated in January 2020 to enhance, cost-effectively deliver high-quality, novel diagnostic services for 21 hospital laboratories in the Huston region. The industry is predicted to grow as a result of such initiatives by major companies to increase their position.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including product, technology, application, and test location from 2023 to 2033.

Report Scope:

Segmentation: Infectious Disease In Vitro Diagnostics Market Report 2022 – 2033

Product (Revenue, USD Million), 2022 – 2033

• Reagents
• Instruments
• Software

Technology (Revenue, USD Million), 2022 – 2033

• Microbiology
• Molecular Diagnostics
• Immunoassay
• Others

Application (Revenue, USD Million), 2022 – 2033

• VRE
• MRSA
• Clostridium Difficile
• Respiratory Virus
• HIV
• CRE
• Hepatitis B
• Candida
• Covid-19
• Chlamydia
• Gonorrhea
• Streptococcus
• Others

Test Location (Revenue, USD Million), 2022 – 2033

• Central Laboratories
• Point of Care
• Others

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA